ImmPACT Bio
A clinical-stage company developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for cancer and autoimmune diseases.
The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells.
Latest ImmPACT Bio News & Features
1 November 2023
14 September 2022
22 July 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze